Skip to main content
JUBILANT PHARMOVA LIMITED logo

JUBILANT PHARMOVA LIMITED — Investor Relations & Filings

Ticker · JUBLPHARMA ISIN · INE700A01033 LEI · 335800C6LDKWF4HQH833 BSE.NS Manufacturing
Open in API
Filings indexed 1,045 across all filing types
Latest filing 2026-05-21 Regulatory Filings
Country IN India
Listing BSE.NS JUBLPHARMA

About JUBILANT PHARMOVA LIMITED

https://www.jubilantpharmova.com/

Jubilant Pharmova Limited is an integrated global pharmaceutical company operating through three primary segments: Pharmaceuticals, Contract Research and Development Services (CRDS), and Proprietary Novel Drugs. The Pharmaceuticals segment specializes in radiopharmaceuticals for nuclear medicine, allergy immunotherapy, and the development and manufacturing of generic formulations. It also provides Contract Development and Manufacturing Organization (CDMO) services for sterile injectables and non-sterile products. The CRDS division offers comprehensive drug discovery and development solutions to biopharmaceutical companies worldwide. Furthermore, the Proprietary Novel Drugs segment focuses on creating innovative therapies for oncology and autoimmune diseases. The company leverages its advanced manufacturing infrastructure and research capabilities to serve global markets with a focus on complex chemistry and specialized healthcare solutions.

Recent filings

Filing Released Lang Actions
Investor Meet
Regulatory Filings Classification · 85% confidence The document is an intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) to stock exchanges about upcoming investor/analyst meetings to discuss the Q4 FY26 earnings presentation. It does not contain financial statements or a report itself, nor does it solicit votes or announce dividends, M&A, or board changes. It is a regulatory disclosure announcement, which falls under the generic Regulatory Filings category.
2026-05-21 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 82% confidence The document is a notification under SEBI Listing Regulations (Regulation 30) to stock exchanges of an upcoming investor/analyst meeting. It does not contain an investor presentation deck, financial statements, or detailed report but is a regulatory announcement of an event. There is no change in board/management, financing, or dividend. It is not an earnings release nor a call transcript. The most appropriate classification is a general regulatory announcement: RNS.
2026-05-21 English
Intimation of Investor Meet
Regulatory Filings Classification · 89% confidence The document is an intimation under SEBI (Listing Obligations and Disclosure Requirements) Regulations, informing stock exchanges of scheduled investor/analyst meetings to discuss the Q4’FY26 earnings presentation. It contains no financial data or the presentation itself, but is a compliance/regulatory disclosure rather than a report, call transcript, earnings release, or presentation. Therefore it is a generic regulatory announcement (fallback category).
2026-05-18 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 78% confidence The document is an intimation under Regulation 30 of SEBI Listing Obligations, notifying stock exchanges of a scheduled investors/analysts meeting. It does not contain financial results, presentations, or substantive report content. It is a regulatory announcement to the exchanges, fitting the fallback category Regulatory Filings (RNS).
2026-05-18 English
Copy of Newspaper Publication
Regulatory Filings Classification · 95% confidence The document is a disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015. It contains copies of newspaper advertisements related to shareholder information campaigns, special windows for re-lodgement of transfer requests of physical shares, and KYC updation and dematerialization of physical share certificates. The content is primarily an announcement and notification to shareholders about these initiatives and does not contain financial statements, audit information, or detailed management discussion. It is not a report itself but an announcement of shareholder-related information and regulatory compliance disclosures. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2026-04-29 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 90% confidence The document is an official communication from Jubilant Pharmova Limited dated April 24, 2026, addressed to stock exchanges, informing about an upcoming Earnings Webinar scheduled for May 22, 2026. It references the financial performance for the fiscal year 2025-26 and provides details about the webinar, including registration instructions and a brief company overview. The document does not contain actual financial results or detailed financial statements but rather announces an event where such information will be discussed. It also mentions that the presentation will be submitted to the stock exchange before the event and hosted on the company website. Given the nature of the document as an announcement of an earnings event and not the earnings release itself, it fits best under the category of a Call Transcript (CT) or Earnings Release (ER). However, since this is an announcement of a webinar (which is a form of earnings call), and not the transcript or the earnings release itself, it is more appropriate to classify it as a Call Transcript (CT) category, which includes earnings calls and related transcripts or announcements. The document length is over 6000 characters, indicating it is not a brief notice but a detailed announcement. Therefore, the best fit is Call Transcript (CT) with high confidence.
2026-04-24 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.